GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sailong Pharmaceutical Group Co Ltd (SZSE:002898) » Definitions » Scaled Net Operating Assets

Sailong Pharmaceutical Group Co (SZSE:002898) Scaled Net Operating Assets : 0.74 (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Sailong Pharmaceutical Group Co Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Sailong Pharmaceutical Group Co's operating assets for the quarter that ended in Mar. 2024 was ¥725.6 Mil. Sailong Pharmaceutical Group Co's operating liabilities for the quarter that ended in Mar. 2024 was ¥119.6 Mil. Sailong Pharmaceutical Group Co's Total Assets for the quarter that ended in Dec. 2023 was ¥813.8 Mil. Therefore, Sailong Pharmaceutical Group Co's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2024 was 0.74.


Sailong Pharmaceutical Group Co Scaled Net Operating Assets Historical Data

The historical data trend for Sailong Pharmaceutical Group Co's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sailong Pharmaceutical Group Co Scaled Net Operating Assets Chart

Sailong Pharmaceutical Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.85 0.78 0.76 0.68 0.69

Sailong Pharmaceutical Group Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.69 0.71 0.70 0.72 0.75

Competitive Comparison of Sailong Pharmaceutical Group Co's Scaled Net Operating Assets

For the Biotechnology subindustry, Sailong Pharmaceutical Group Co's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sailong Pharmaceutical Group Co's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sailong Pharmaceutical Group Co's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Sailong Pharmaceutical Group Co's Scaled Net Operating Assets falls into.



Sailong Pharmaceutical Group Co Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Sailong Pharmaceutical Group Co's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2023 )
=(Operating Assets (A: Dec. 2023 )-Operating Liabilities (A: Dec. 2023 ))/Total Assets (A: Dec. 2022 )
=(724.582-140.839)/848.015
=0.69

where

Operating Assets(A: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=813.844 - 89.262
=724.582

Operating Liabilities(A: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=277.962 - 25.118 - 112.005
=140.839

Sailong Pharmaceutical Group Co's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2024 )
=(Operating Assets (Q: Mar. 2024 )-Operating Liabilities (Q: Mar. 2024 ))/Total Assets (Q: Dec. 2023 )
=(725.62-119.556)/813.844
=0.74

where

Operating Assets(Q: Mar. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=784.308 - 58.688
=725.62

Operating Liabilities(Q: Mar. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=246.802 - 22.878 - 104.368
=119.556

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sailong Pharmaceutical Group Co Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Sailong Pharmaceutical Group Co's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Sailong Pharmaceutical Group Co (SZSE:002898) Business Description

Traded in Other Exchanges
N/A
Address
No. 47, Haibin South Road, 2nd Floor, Everbright International Trade Center, Guangdong Province, Zhuhai, CHN, 519015
Zhuhai Sailong Pharmaceutical Co Ltd is the pharmaceutical company. It is mainly engaged in the development, production, marketing and technical services of pharmaceuticals. The company's products are mainly concentrated in the fields of the nervous system, cardiovascular and digestive system. The product range includes monosialin tetrahexose ganglioside sodium injections, brain protein hydrolyzate for injections, clindamycin phosphate for injections, pantoprazole sodium for injections and milrinon injections, among others.
Executives
Tang Lin Director
Long Zhi Xiang Director
Deng Yong Jun Supervisors
Zhou Bei Supervisors
Li Jian Feng Directors, executives

Sailong Pharmaceutical Group Co (SZSE:002898) Headlines

No Headlines